prikaz prve stranice dokumenta SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
  Preuzmi
PDF 665.61 KB
Znanstveni rad - Izvorni znanstveni rad
SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
Biomedicines, 10 (2022), 12; 3237. https://doi.org/10.3390/biomedicines10123237
Nedić Erjavec, Gordana; Grubor, Mirko; Živković, Maja; Božina, Nada; Šagud, Marina; Nikolac Perković, Matea; Mihaljević-Peleš, Alma; Pivac, Nela; Švob Štrac, Dubravka

Citirajte ovaj rad

Nedić Erjavec, G., Grubor, M., Živković, M., Božina, N., Šagud, M., Nikolac Perković, M. ... Švob Štrac, D. (2022). SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines, 10. (12). doi: 10.3390/biomedicines10123237

Nedić Erjavec, Gordana, et al. "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism." Biomedicines, vol. 10, br. 12, 2022. https://doi.org/10.3390/biomedicines10123237

Nedić Erjavec, Gordana, Mirko Grubor, Maja Živković, Nada Božina, Marina Šagud, Matea Nikolac Perković, Alma Mihaljević Peleš, Nela Pivac i Dubravka Švob Štrac. "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism." Biomedicines 10, br. 12 (2022). https://doi.org/10.3390/biomedicines10123237

Nedić Erjavec, G., et al. (2022) 'SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism', Biomedicines, 10(12). doi: 10.3390/biomedicines10123237

Nedić Erjavec G, Grubor M, Živković M, Božina N, Šagud M, Nikolac Perković M, i sur.. SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism. Biomedicines [Internet]. 13.12.2022. [pristupljeno 20.12.2024.];10(12). doi: 10.3390/biomedicines10123237

G. Nedić Erjavec, et al., "SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism", Biomedicines, vol. 10, br. 12, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:746134. [Citirano: 20.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:746134
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)SLC6A3, HTR2C and HTR6 Gene Polymorphisms and the Risk of Haloperidol-Induced Parkinsonism
AutorGordana Nedić Erjavec
AutorMirko Grubor
AutorMaja Živković
AutorNada Božina
AutorMarina Šagud
AutorMatea Nikolac Perković
AutorAlma Mihaljević-Peleš
AutorNela Pivac
AutorDubravka Švob Štrac
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA TEMELJNU I KLINIČKU FARMAKOLOGIJU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PSIHIJATRIJU I PSIHOLOŠKU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Temeljne medicinske znanosti
Farmakologija
Sažetak (engleski)
Antipsychotic-induced parkinsonism (AIP) is the most common type of extrapyramidal side effect (EPS), caused by the blockage of dopamine receptors. Since dopamine availability might influence the AIP risk, the dopamine transporter (DAT) and serotonin receptors (5-HTRs), which modulate the dopamine release, may be also involved in the AIP development. As some of the individual differences in the susceptibility to AIP might be due to the genetic background, this study aimed to examine the associations of SLC6A3, HTR2C and HTR6 gene polymorphisms with AIP in haloperidol-treated schizophrenia patients. The Extrapyramidal Symptom Rating Scale (ESRS) was used to evaluate AIP as a separate entity. Genotyping was performed using a PCR, following the extraction of blood DNA. The results revealed significant associations between HTR6 rs1805054 polymorphism and haloperidol-induced tremor and rigidity. Additionally, the findings indicated a combined effect of HTR6 T and SLC6A3 9R alleles on AIP, with their combination associated with significantly lower scores of ESRS subscale II for parkinsonism, ESRS-based tremor or hyperkinesia and ESRS subscales VI and VIII. These genetic predictors of AIP could be helpful in better understanding its pathophysiology, recognizing the individuals at risk of developing AIP and offering personalized therapeutic strategies for the patients suffering from this EPS.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 10, br. 12, 3237
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines10123237
URN:NBNurn:nbn:hr:105:746134
Datum objave publikacije2022-12-13
URL dokumentahttps://www.mdpi.com/2227-9059/10/12/3237
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-04-26 12:15:09